Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Horizon Therapeutics Pub L's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Horizon Therapeutics Pub L's position in the market.
Horizon Therapeutics plc (NASDAQ: HZNP) has released a Rule 8.1 dealing disclosure under the Irish Takeover Panel Act. The disclosure pertains to Timothy P. Walbert, a person acting in concert with the offeree (as a director of Horizon Therapeutics). On June 1, 2023, Walbert purchased 279 ordinary shares at a price of $76.07 per unit.
Following this transaction, Walbert owns or controls 3,737,295 ordinary shares, representing 1.633% of the company's relevant securities. The disclosure also corrects a previous error in the January 6, 2023 Rule 8.1 Disclosure, which incorrectly stated Walbert's ownership as 3,620,605 shares. The correct number of shares owned on January 5, 2023, was 3,737,016.
